Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

Cellular Biomedicine Group, Inc.

Form 8-K

November 29, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 29, 2016

CELLULAR BIOMEDICINE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-36498 86-1032927

(State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

19925 Stevens Creek Blvd., Suite 100 95014

Cupertino, California

)J014

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (408) 973-7884

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

Item 7.01 Regulation FD Disclosure.

On November 29, 2016, Cellular Biomedicine Group, Inc. (the "Company") issued a press release announcing the initiation of its Phase I clinical trial for utilizing C-CAR011 in treating patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press Release dated November 29, 2016

2

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,

Inc.

Date: November 29, 2016 By: /s/ Bizuo (Tony) Liu

Bizuo (Tony) Liu Chief Financial Officer

3